Prasugrel resistance: Fact or fiction

被引：30

作者：

Alexopoulos, Dimitrios ^{[1
]}

机构：

[1] Patras Univ Hosp, Dept Cardiol, Patras 26500, Greece

来源：

PLATELETS | 2012年 / 23卷 / 02期

关键词：

Prasugrel; antiplatelets; clopidogrel; ASPIRIN-TREATED PATIENTS; HIGH-DOSE CLOPIDOGREL; PLATELET-AGGREGATION; ANTIPLATELET THERAPY; DIABETES-MELLITUS; ACTIVE METABOLITE; ACHIEVES GREATER; INHIBITION; REACTIVITY; NONRESPONDERS;

D O I：

10.3109/09537104.2011.600478

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Prasugrel is a third-generation thienopyridine that inhibits ADP-induced platelet activation by irreversibly blocking the P2Y12 receptor. Given in healthy volunteers in dosages used clinically, it invariably inhibits platelet aggregation. When administered in patients, it has been shown to result in a faster, more consistent and stronger inhibition of platelet aggregation compared with the most widely used clopidogrel. However, cases of inadequate platelet inhibition or of the so-called 'resistance' to prasugrel have been occasionally reported. The focus of this review is prasugrel resistance prevalence, mechanisms and potential clinical implications.

引用

收藏

页码：83 / 90

页数：8

相关论文

共 28 条

[1] Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel The Importance of CYP2C19*2 Genotyping [J].

Alexopoulos, Dimitrios ;

Dimitropoulos, Gerasimos ;

Davlouros, Periklis ;

Xanthopoulou, Ioanna ;

Kassimis, George ;

Stavrou, Eleana F. ;

Hahalis, George ;

Athanassiadou, Aglaia .

JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (04) :403-410

[2] Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease [J].

Angiolillo, DJ ;

Fernandez-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Cavallari, U ;

Trabetti, E ;

Sabaté, M ;

Jimenez-Quevedo, P ;

Hernández, R ;

Moreno, R ;

Escaned, J ;

Alfonso, F ;

Bañuelos, C ;

Costa, MA ;

Bass, TA ;

Pignatti, PF ;

Macaya, C .

THROMBOSIS RESEARCH, 2005, 116 (06) :491-497

[3] A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial [J].

Angiolillo, Dominick J. ;

JoseBadimon, Juan ;

Saucedo, Jorge F. ;

Frelinger, Andrew L. ;

Michelson, Alan D. ;

Jakubowski, Joseph A. ;

Zhu, Baojin ;

Ojeh, Clement K. ;

Baker, Brian A. ;

Effron, Mark B. .

EUROPEAN HEART JOURNAL, 2011, 32 (07) :838-846

[4] Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate [J].

Bonello, Laurent ;

Tantry, Udaya S. ;

Marcucci, Rossella ;

Blindt, Ruediger ;

Angiolillo, Dominick J. ;

Becker, Richard ;

Bhatt, Deepak L. ;

Cattaneo, Marco ;

Collet, Jean Philippe ;

Cuisset, Thomas ;

Gachet, Christian ;

Montalescot, Gilles ;

Jennings, Lisa K. ;

Kereiakes, Dean ;

Sibbing, Dirk ;

Trenk, Dietmar ;

Van Werkum, Jochem W. ;

Paganelli, Franck ;

Price, Matthew J. ;

Waksman, Ron ;

Gurbel, Paul A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (12) :919-933

[5] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].

Brandt, J. T. ;

Close, S. L. ;

Iturria, S. J. ;

Payne, C. D. ;

Farid, N. A. ;

Ernest, C. S., II ;

Lachno, D. R. ;

Salazar, D. ;

Winters, K. J. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436

[6] Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo [J].

Erlinge, David ;

Varenhorst, Christoph ;

Braun, Oscar O. ;

James, Stefan ;

Winters, Kenneth J. ;

Jakubowski, Joseph A. ;

Brandt, John T. ;

Sugidachi, Atsuhiro ;

Siegbahn, Agneta ;

Wallentin, Lars .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (24) :1968-1977

[7] Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans [J].

Farid, Nagy A. ;

Kurihara, Atsushi ;

Wrighton, Steven A. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (02) :126-142

[8] Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects [J].

Fontana, P ;

Dupont, A ;

Gandrille, S ;

Bachelot-Loza, C ;

Reny, JL ;

Aiach, M ;

Gaussem, P .

CIRCULATION, 2003, 108 (08) :989-995

[9] Clopidogrel effect on platelet REactivity in patients with stent thrombosis - Results of the CREST study [J].

Gurbel, PA ;

Bliden, KP ;

Samara, W ;

Yoho, JA ;

Hayes, K ;

Fissha, MZ ;

Tantry, US .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (10) :1827-1832

[10] Drug insight: clopidogrel nonresponsiveness [J].

Gurbel, Paul A. ;

Tantry, Udaya S. .

NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (07) :387-395